MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Latest News
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, develop...globenewswire.com — Apr 29, 2026MXCT Data Insights
- Dark pool activity detected in the last 5 trading days
Subscribe for full dark pool analysis, institutional flow, and real-time alerts.
📊 Key Statistics
Market Cap$94M
P/E Ratio—
EPS (TTM)—
EPS YoY—
Revenue YoY—
Float—
Short Float %—
Inst. Ownership—
Sector RS—
📈 Fundamentals
ROE—
ROIC—
ROA—
Current Ratio—
Debt/Equity—
Gross Margin—
Net Margin—
Dividend Yield—
Next Earnings—
⚡ Options Summary
Call OI—
Put OI—
P/C Ratio (OI)—
Gamma Environment—
Max Pain—
Call Wall—
Put Wall—
🎯 Analyst Estimates
Consensus Target—
High Target—
Low Target—
Analysts—
Upside/Downside—
📋 Quarterly Financials
| Period |
Revenue |
Rev YoY |
EPS |
EPS YoY |
Gross Margin |
🔥 Recent Options Flow
| Type | Strike | Exp | Size | Premium | Time |
🏛️ Institutional Trades
| Type | Price | Size | Value | Venue | Time |
🏦 Top Institutional Holders
| Institution | Shares | Value | % of Class |